A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs PF 6293620 (Primary) ; PF 6293620 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 08 May 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.